TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

GENERLAC

LACTULOSE Osmotic Activity
Gastroenterology Approved 1996-10-31
1
Indication
--
Phase 3 Trials
29
Years on Market

Details

Status
Prescription
First Approved
1996-10-31
Routes
ORAL, RECTAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: LACTULOSE

GENERLAC Approval History

Loading approval history...

What GENERLAC Treats

1 indications

GENERLAC is approved for 1 conditions since its original approval in 1996. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hepatic Encephalopathy
Source: FDA Label

Drugs Similar to GENERLAC

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

GENERLAC FDA Label Details

Pro

Indications & Usage

For the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Controlled studies have shown that lactulose solution therapy reduces the blood ammonia levels by 25 to 50%; this is generally paralleled by an improvement in the patients' mental state and by an improvement in EEG patterns. The clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. An increase in patients' protein tolerance is also frequently observed with lactulose solution therapy. In the trea...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.